A growth-stage investor and former operator focused on scaling SaaS and consumer-facing tech companies, with experience in commercial strategy, fundraising and M&A execution. Her profile includes operator roles at startups and venture investments across B2B software, marketplaces and digital consumer brands; Ashley Meredith is frequently engaged as board observer or independent director supporting KPI-driven growth and go-to-market optimization. She is positioned for roles that bridge operator instincts and investment discipline, prioritizing unit economics, retention metrics and capital-efficient expansion.
A growth-stage investor and former operator focused on scaling SaaS and consumer-facing tech companies, with experience in commercial strategy, fundraising and M&A execution. Her profile includes operator roles at startups and venture investments across B2B software, marketplaces and digital consumer brands; Ashley Meredith is frequently engaged as board observer or independent director supporting KPI-driven growth and go-to-market optimization. She is positioned for roles that bridge operator instincts and investment discipline, prioritizing unit economics, retention metrics and capital-efficient expansion.
Focuses on growth-stage SaaS, marketplaces and consumer tech where operator experience accelerates commercial scale. Emphasizes KPI-driven underwriting—unit economics, retention, LTV/CAC and margin expansion—favoring capital-efficient paths to repeatable revenue. Deploys staged capital with follow-on reserves, active board-level engagement and go-to-market playbooks to de-risk commercialization. Time horizon targets durable scale rather than quick exits; risk discipline centers on measurable traction, customer economics and founder alignment, with preference for repeatable GTM and strong unit-level margins.
Focuses on growth-stage SaaS, marketplaces and consumer tech where operator experience accelerates commercial scale. Emphasizes KPI-driven underwriting—unit economics, retention, LTV/CAC and margin expansion—favoring capital-efficient paths to repeatable revenue. Deploys staged capital with follow-on reserves, active board-level engagement and go-to-market playbooks to de-risk commercialization. Time horizon targets durable scale rather than quick exits; risk discipline centers on measurable traction, customer economics and founder alignment, with preference for repeatable GTM and strong unit-level margins.
| Trades 3722 | Longs Won 2064/3722 55% | Profit Factor 3.8 |
| Profitability | Shorts Won 0/0 0% | Standard Deviation $261,497.97 |
| Average Win $64,031.17 | Best Trade (Oct 15) $12.53M | Sharpe Ratio -8.44 |
| Average Loss -$20,969.97 | Worst Trade (Oct 15) -$399,483.46 | Z-Score 0.15 (12.25%) |
| Commissions $0 | Avg. Trade Length 9m 2w 1d | Expectancy $26,456.44 |
| Loss Size | 100% | 90% | 80% | 70% | 60% | 50% | 40% | 30% | 20% | 10% |
| Probability of Loss | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% |
| Consecutive Losing Trades | 26,316 | 23,684 | 21,053 | 18,421 | 15,789 | 13,158 | 10,526 | 7,895 | 5,263 | 2,632 |
| Symbol | Quantity | Cost | Value | Comm. | Profit ($) | Gain (%) | Change |
|---|---|---|---|---|---|---|---|
AAOI Applied Optoelectronics, Inc. | 3,807 | $322,034.2 | $307,872.09 | - | -$14,162.11 | -4.4% | -6.205% |
AAON Aaon Inc. | 1,864 | $236,467 | $142,139.32 | - | -$94,327.68 | -39.89% | -5.309% |
AAPL Apple Inc. | 38,715 | $9.21M | $13.34M | - | $4.12M | 44.76% | +0.443% |
AARD Aardvark Therapeutics, Inc. | 10,066 | $38,653.44 | $39,157.75 | - | $504.31 | 1.3% | +0.26% |
ABBV AbbVie Inc. | 7,378 | $1.59M | $2.12M | - | $528,684.82 | 33.17% | +1.475% |
ABG Asbury Automotive Group Inc. | 1,488 | $333,889.68 | $255,459.84 | - | -$78,429.84 | -23.49% | +5.995% |
ABNB Airbnb, Inc. | 2,992 | $396,152.7 | $515,925.52 | - | $119,772.82 | 30.23% | +3.217% |
ABR Arbor Realty Trust Inc. | 17,277 | $93,641 | $49,153.06 | - | -$44,487.94 | -47.51% | +9.004% |
ABT Abbott Laboratories | 5,597 | $507,906 | $585,278.29 | - | $77,372.29 | 15.23% | +1.554% |
ABUS Arbutus Biopharma Corporation | 18,300 | $88,023.01 | $77,683.5 | - | -$10,339.51 | -11.75% | +1.313% |
ACA Arcosa Inc. | 2,253 | $244,371.11 | $331,236.06 | - | $86,864.95 | 35.55% | +0.007% |
ACAD Acadia Pharmaceuticals Inc. | 12,694 | $320,446.9 | $249,944.86 | - | -$70,502.04 | -22% | +2.286% |
ACH Accendra Health, Inc. | 20,113 | $46,542.41 | $5,748.3 | - | -$40,794.11 | -87.65% | -8.632% |
ACI Albertsons Companies, Inc. | 16,200 | $219,186 | $213,030 | - | -$6,156 | -2.81% | +0.535% |
ACIW ACI Worldwide, Inc. | 11,546 | $475,501.64 | $602,470.28 | - | $126,968.64 | 26.7% | +2.173% |
ACLS Axcelis Technologies, Inc. | 2,622 | $211,197.17 | $297,282.36 | - | $86,085.19 | 40.76% | -4.409% |
ACMR Acm Research Inc. | 2,956 | $375,087 | $166,496.7 | - | -$208,590.3 | -55.61% | -7.845% |
ACN Accenture plc Class A | 1,628 | $407,981.7 | $367,016.32 | - | -$40,965.38 | -10.04% | +4.875% |
ACRE Ares Commercial Real Estate Corporation | 52,842 | $251,948.47 | $192,344.88 | - | -$59,603.59 | -23.66% | +4% |
ACTG Acacia Research Corporation | 14,416 | $54,776.59 | $62,060.88 | - | $7,284.29 | 13.3% | +0.116% |